Indian drugmakers need more FDA approvals to maintain growth

02/16/2009 | Business Standard (India)

Indian pharmaceutical companies including Dr. Reddy's Laboratories and Sun Pharma would require at least 12 to 14 FDA approvals to achieve their 20% sales growth target in the U.S., according to a Credit Suisse report. Ranbaxy Laboratories, which is under investigation for manufacturing violations, needs 20 more approvals to hit the target this year, the report said.

View Full Article in:

Business Standard (India)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY